Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: A prospective comparative study

Digestive Diseases and Sciences

Volumn 58, Issue 3, 2013, Pages 865-871

  Jang, Sung Ill ^a,b   Kim, Jie Hyun ^a,b   You, Jung Whan ^a,b   Rhee, Kwangwon ^a,b   Lee, Se Joon ^a,b   Kim, Ho Gak ^c   Han, Jimin ^c   Shin, Im Hee ^c   Park, Sang Heum ^d   Lee, Dong Ki ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Biliary tract neoplasm; Drug eluting stent; Malignant obstruction; Paclitaxel; Pancreatic cancer

Indexed keywords

ANTIBIOTIC AGENT; CAPECITABINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CHOLESTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; COVERED METAL STENT; DRUG EFFICACY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; METAL STENT; METALLIC STENT COVERED WITH A PACLITAXEL-INCORPORATED MEMBRANE; PANCREATITIS; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHOLESTASIS; DRUG-ELUTING STENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 84876694634     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2472-1     Document Type: Article

References (30)

1. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet. 1994;344:1655-1660.
2. Andersen JR, Sorensen SM, Kruse A, Rokkjaer M, Matzen P. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut. 1989;30:1132-1135.
3. Wagner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy. 1993;25:213-218.
4. Nakai Y, Isayama H, Komatsu Y, et al. Efficacy and safety of the covered wallstent in patients with distal malignant biliary obstruction. Gastrointest Endosc. 2005;62:742-748.
5. Park do H, Kim MH, Choi JS, et al. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. Clin Gastroenterol Hepatol. 2006;4:790-796.
6. Kim HS, Lee DK, Kim HG, et al. Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study. Gastrointest Endosc. 2002;55:359-365.
7. Hausegger KA, Kleinert R, Lammer J, Klein GE, Fluckiger F. Malignant biliary obstruction: histologic findings after treatment with self-expandable stents. Radiology. 1992;185:461-464.
8. Gillams A, Dick R, Dooley JS, Wallsten H, El-Din A. Self-expandable stainless steel braided endoprosthesis for biliary strictures. Radiology. 1990;174:137-140.
9. Knyrim K, Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy. 1993;25:207-212.
10. Dhanikula AB, Panchagnula R. Localized paclitaxel delivery. Int J Pharm. 1999;183:85-100.
11. Lee DK, Kim HS, Kim KS, et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc. 2005;61:296-301.
12. Suk KT, Kim JW, Kim HS, et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc. 2007;66:798-803.
13. Kalinowski M, Alfke H, Kleb B, Durfeld F, Joachim Wagner H. Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: possible topical application in malignant bile duct obstructions. Invest Radiol. 2002;37:399-404.
14. Khan I, Smith N, Jones E, Finch DS, Cameron RE. Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part II: in vivo investigation. Biomaterials. 2005;26:633-643.
15. Lee DK. Drug-eluting stent in malignant biliary obstruction. J Hepatobiliary Pancreat Surg. 2009;16:628-632.
16. Hausegger KA, Thurnher S, Bodendorfer G, et al. Treatment of malignant biliary obstruction with polyurethane-covered wallstents. Am J Roentgenol (AJR). 1998;170:403-408.
17. Kim JH, Song HY, Shin JH, Jung HY, Kim SB, Park SI. Membrane degradation of covered stents in the upper gastrointestinal tract: frequency and clinical significance. J Vasc Interv Radiol. 2008;19:220-224.
18. Kim JH, Kim M, Yang S, et al. The effect of multiplex paclitaxel emission stent using pluronic mixture membrane in biliary tract. Gastrointest Endosc. 2011;73:AB344.
19. Song TJ, Lee SS, Yun SC, et al. Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot study. Gastrointest Endosc. 2011;73:727-733.
20. Loew BJ, Howell DA, Sanders MK, et al. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc. 2009;70:445-453.
21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-1014.
22. Lee SS, Shin JH, Han JM, et al. Histologic influence of paclitaxel-eluting covered metallic stents in a canine biliary model. Gastrointest Endosc. 2009;69:1140-1147.
23. Nakai Y, Isayama H, Kawabe T, et al. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine. Pancreas. 2008;37:405-410.
24. Merl MY, Li J, Saif MW. The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO gastrointestinal cancers symposium". Orlando, FL, USA. January 22-24, 2010. JOP. 2010;11:148-150.
25. Wagner AD, Buechner-Steudel P, Moehler M, et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer. 2009;101:1846-1852.
26. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004;15:770-774.
27. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
28. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-5518.
29. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol. 2000;18:860-867.
30. Baron TH. Endoscopic retrograde cholangiopancreatography. Endoscopy. 2010;42:938-943.